8 results about "Immune Evasions" patented technology

The present invention provides compositions for the prevention and treatment of genital herpes, comprising nucleoside modified mRNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.

This invention provides an H3N2 influenza mRNA vaccine targeting the tandem HA and NA proteins and its preparation method, relating to the field of vaccine preparation technology. The H3N2 influenza mRNA vaccine is obtained by linking the conserved amino acid sequences of HA and NA of H3N2 with GGGSGGGSGGGSGGGS, and the amino acid sequence of the H3N2 influenza mRNA vaccine is shown in SEQ ID NO.1, and the nucleic acid sequence is shown in SEQ ID NO.2. This invention overcomes the shortcomings of existing technologies, improves the protective effect of the vaccine against H3N2 influenza, and enables it to better cope with immune evasion from the latest emerging H3N2 variants.

We describe compositions of DNA donor molecules compatible with various gene insertion methods, offering key advantages in delivery, nuclear localization, and immune evasion. The modified DNA donor molecules are predominantly single-stranded but include short regions of double-stranded DNA to reconstruct enzyme binding sites, and can be combined with other methods to enhance donor recruitment to the cell nucleus.

The present disclosure provides methods of treating immune evasive cancers using surface functionalized particles alone or in combination with cancer therapeutics.

The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and / or clearance in tissues, receptor uptake and / or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and / or modulation of a cell's status, function, and / or activity.

Invasive fungal disease (IFD) constitutes an increasing health concern due to growing numbers of patients at risk for opportunistic fungal infections. Among the fungi capable of inducing opportunistic infections the yeast Candida albicans is clinically the most important. Immune evasion proteins like the pH-regulated antigen 1 (Pra1) and the translation elongation factor 1 (Tef1), which are expressed on the fungal surface and are also secreted, are major drivers of pathogenicity. Therefore, novel monoclonal antibodies (mAb) binding these proteins have been developed. In an in vivo mouse model of high-dose septic C. albicans infection, therapeutic application of mAb against Pra1 reduced clinical symptoms of the disease. Prophylactically, mAb against Tef1 protected mice from clinical disease and prolonged survival. The mABs of the present invention may also be efficacious in patients at risk or with already established IFD.

The present application belongs to the technical field of medicine and pharmacy, and in particular relates to an application of proto-prosolan in preparation of a Streptococcus suis type 2 capsule inhibitor. The present application discloses that proto-prosolan can significantly weaken the pathogenicity and immune escape ability of Streptococcus suis type 2 by inhibiting capsule synthesis, and then effectively plays an anti-infection role. Compared with vaccines, antibodies and phage enzymes and other highly limited anti-capsule strategies specific to serotypes, proto-prosolan, as an anti-toxicity inhibitor of Streptococcus suis type 2, has potential advantages such as broad spectrum, and has important scientific significance and application value for the research and development of new anti-drugs in the future. The proto-prosolan can be applied to the preparation of a Streptococcus suis type 2 capsule inhibitor and a drug for preventing and treating Streptococcus suis type 2 infection.

The present invention relates to: an immuno-oncology composition comprising an anti-MUC1 antibody or an antigen-binding fragment thereof that specifically binds to a polypeptide comprising the C-terminal extracellular domain of Mucin 1 (MUC1); and a use for inducing an immuno-oncology response in a subject by using same. The anti-MUC1 antibody or antigen-binding fragment thereof that specifically binds to a polypeptide comprising the C-terminal extracellular domain of MUC1 according to the present invention does not exhibit direct cytotoxicity to cancer cells, induces an increase in the activity of immune cells, and exhibits antibody-dependent cellular cytotoxicity (ADCC) by inhibiting immune evasion of cancer. Therefore, the anti-MUC1 antibody or antigen-binding fragment thereof can be used as various types of immuno-oncology agents, immuno-oncology adjuvants, or combination therapeutic agents for inducing an immune response in a subject and enhancing an anticancer effect.